of aldehyde dehydrogenase. Our finding of a biphasic acetaldehyde metabolism accords with earlier studies on purified sheep liver and human liver cytosolic enzyme.¹²⁻¹⁴ Biphasic kinetics may have several causes: (a) enzymes may exhibit co-operative behaviour,¹⁶ (b) different isoenzymes may be present, and (c) one enzyme may consist of non-equivalent subunits which have a different affinity for the substrate. The difference in metabolic rates between flushers and non-flushers was unlikely to be due to a difference in enzyme concentration, since the elimination in phase I was almost identical for the two groups. Our data support the hypothesis of a difference in aldehyde dehydrogenase activity between flushers and non-flushers, which is probably due to two types of high affinity binding sites for acetaldehyde. Hypothetically this difference in enzyme activity between those at risk of developing late complications and those who are not could be used after further refinement to identify patients at risk early by using a simple blood test. Determining the biochemical basis of protection against late complications through the change in enzyme activity will be an even more important step.

Requests for reprints should be addressed to: Dr H Öhlin, Department of Medicine, Malmö General Hospital, S-214 01 Malmö, Sweden.

References

- Bertram F, Bendfeldt E, Otto H. Indikationen und Erfolge der peroralen Behandlung des Diabetes mellitus mit einem Sulfonylharnstoffderivat. *Dtsch Med Wochenschr* 1956;**81**:274-8.
- Leslie RDG, Pyke DA. Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes. *Br Med J* 1978;iii:1519-21.
- Leslie RDG, Barnett AH, Pyke DA. Diabetic retinopathy and chlorpropamide-alcohol flushing. *Lancet* 1979;i:997-9.
- Barnett AH, Pyke DA. Chlorpropamide-alcohol flushing and large-vessel disease in non-insulin-dependent diabetes. *Br Med J* 1980;**281**:261-2.
- Jerntorp P, Almér LO. Chlorpropamide-alcohol flushing in relation to macro-angiopathy and peripheral neuropathy in non-insulin dependent diabetes. *Acta Med Scand* 1981; **656**, suppl:33-6.
- Barnett AH, Leslie RDG, Pyke DA. Chlorpropamide-alcohol flushing and proteinuria in non-insulin-dependent diabetics. *Br Med J* 1981;ii:522-3.
- Jerntorp P, Öhlin H, Bergström B, Almér LO. Increase in plasma acetaldehyde; an objective indicator of the chlorpropamide-alcohol flush. *Diabetes* 1981;**30**:788-91.
- Jerntorp P, Almér LO, Melander A. Is the blood chlorpropamide critical in chlorpropamide-alcohol flush? *Lancet* 1981;ii:165-6.
- Jerntorp P, Almér LO, Melander A. Chlorpropamide-induced inhibition of alcohol metabolism, the cause of CPAF. *Diabetologia* 1981;**21**:287.
- Barnett AH, Gonzalez-Auvert C, Pyke DA, et al. Blood concentrations of acetaldehyde during chlorpropamide-alcohol flush. *Br Med J* 1981;**283**:939-41.
- Deitrich RA. Tissue and subcellular distribution of mammalian aldehyde-oxidizing capacity. *Biochem Pharmacol* 1966;**15**:1911-22.
- Greenfield NJ, Pietruszko R. Isolation via affinity chromatography and characterization of the isoenzymes. *Biochem Biophys Acta* 1977;**483**:35-45.
- Inoue K, Nishimukai H, Yamasawa K. Purification and partial characterization of aldehyde dehydrogenase from human erythrocytes. *Biochem Biophys Acta* 1979;**569**:117-23.
- MacGibbon AKH, Blackwell LF, Buckley PD. Kinetics of sheep-liver aldehyde dehydrogenase. *Eur J Biochem* 1977;**77**:91-100.
- Inoue K, Ohbora Y, Yamasawa K. Metabolism of acetaldehyde by human erythrocytes. *Life Sci* 1978;**23**:179-84.
- Koshland DR Jr. In: Boyer PD, ed. *The enzymes*, Vol 1. New York: Academic Press, 1970:342-96.

(Accepted 30 June 1982)

High serum vitamin B₁₂ binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma

F J PARADINAS, W M MELIA, M L WILKINSON, B PORTMANN, P J JOHNSON, I M MURRAY-LYON, ROGER WILLIAMS

Abstract

Ten (9.3%) of 107 patients with hepatocellular carcinoma had considerably increased serum unsaturated vitamin B₁₂ binding capacity. All 10 were young (mean 21 years), had no serum alpha-fetoprotein, and no underlying cirrhosis; all had a longer survival compared with patients without increased serum unsaturated vitamin B₁₂ binding capacity in the study. Seven of the 10 patients

had fibrolamellar hepatocellular carcinoma, a recently recognised histological variant, which was found in only one young patient without increased serum unsaturated vitamin B₁₂ binding capacity and no alpha-fetoprotein among the remaining 97. This high degree of correlation between increased serum unsaturated vitamin B₁₂ binding capacity and fibrolamellar hepatocellular carcinoma has not been reported before. Increased serum unsaturated vitamin B₁₂ binding capacity may be of considerable help in diagnosis, prognosis, and monitoring treatment of this well-defined group of patients with hepatocellular carcinoma but no alpha-fetoprotein.

Departments of Histopathology and Gastroenterology, Charing Cross Hospital and Medical School, London W6 8RF

F J PARADINAS, MRCPATH, senior lecturer and honorary consultant pathologist

I M MURRAY-LYON, MD, FRCP, consultant physician and gastroenterologist

Liver Unit, King's College Hospital and Medical School, London SE5 9RS

W M MELIA, MRCP, research fellow

M L WILKINSON, BSC, MRCP, research fellow

B PORTMANN, MD, MRCPATH, consultant histopathologist and honorary senior lecturer

P J JOHNSON, MRCP, consultant physician and honorary senior lecturer

ROGER WILLIAMS, MD, FRCP, consultant physician

Introduction

A fibrosing variant of hepatocellular carcinoma found in young people was first noted by Edmondson in 1958,¹ but the clinical features of this variant, including its development in the non-cirrhotic liver and its relatively good prognosis, were not reported until 1976.² Because of the distinct eosinophilic cytoplasm of the tumour cells and the parallel arrangement of the collagen in the conspicuous fibrous septa the tumour was called eosinophilic hepatoma with lamellar fibrosis, which was later shortened to fibrolamellar carcinoma.³ There have also been reports⁴⁻⁶ of

hepatocellular carcinoma in adolescents and young adults (adolescent hepatoma) with no underlying cirrhosis and appreciably increased serum vitamin B₁₂ binding capacity due either to production or to modification of the binding protein transcobalamin I by the tumour,^{7 8} but there are no detailed histological studies of hepatocellular carcinoma associated with increased serum unsaturated vitamin B₁₂ binding capacity.

In a study of the clinical and histological features of 107 patients with hepatocellular carcinoma we measured their serum unsaturated vitamin B₁₂ binding capacity and alpha-fetoprotein concentrations. A raised concentration of serum vitamin B₁₂ binding capacity occurred mainly in patients with fibrolamellar carcinoma and can be used as a marker of this type of tumour.

Patients and methods

The 107 patients (aged 15-75 years) with histologically confirmed hepatocellular carcinoma comprised 87 men and 20 women, nine of whom had taken oral contraceptive preparations at some time. Sixty-eight had underlying cirrhosis and 78 had raised serum concentrations of alpha-fetoprotein (ranging from 35 to 1.25 ng/ml by radioimmunoassay). The material examined came from needle biopsies, surgical biopsies, or tumour resection specimens. Three biopsy specimens from patients with increased serum unsaturated vitamin B₁₂ binding capacity and fibrolamellar carcinoma were also examined by electronmicroscopy. Serum unsaturated vitamin B₁₂ binding capacity was measured by radioassay⁹ in serum samples collected before treatment and stored at -20°C (normal values 0.7-1.6 µg/l).

Results

CLINICAL FEATURES

Eight of 107 patients had characteristic features of fibrolamellar carcinoma (figure); of these, seven as well as three others without diagnostic fibrolamellar features had considerably increased serum unsaturated vitamin B₁₂ binding capacity (table I), the correlation between increased serum unsaturated vitamin B₁₂ binding capacity and fibrolamellar carcinoma being highly significant (table II). Abnormally high serum vitamin B₁₂ concentrations were present in the six patients in whom these were measured in the same pretreatment samples (table I).

Serial values were available in seven of the patients with increased serum unsaturated vitamin B₁₂ binding capacity. In four, who showed no clinical evidence of response to chemotherapy, values gradually rose, with death occurring at six, 12, 14, and 14 months after diagnosis. The maximum increase in serum unsaturated vitamin B₁₂ binding capacity between diagnosis and death was 75%. In a fifth patient the serum unsaturated vitamin B₁₂ binding capacity fell by 75% during a remission induced by adriamycin and subsequently rose again to exceed the presentation value, with relapse, disease progression, and death at 20 months. In the two patients who underwent hemihepatectomy serum unsaturated vitamin B₁₂ binding capacity returned to normal after operation.

The one-year projected survival by the life-tables method shows that 79% of patients with hepatocellular carcinoma associated with increased serum unsaturated vitamin B₁₂ binding capacity were alive, which compares favourably with 28% (22 of 77 patients not withdrawn

Fibrolamellar carcinoma composed of eosinophilic cells forming cords separated by parallel collagen lamellae. (Haematoxylin and eosin × 120)

TABLE II—Correlation between histology and increased serum unsaturated vitamin B₁₂ binding capacity (UBBC)

Histology	Increased UBBC (No of patients):		Total
	With	Without	
Fibrolamellar hepatocellular carcinoma	7	1	8
Other hepatocellular carcinoma	3	96	99
Total	10	97	107

$\chi^2 = 52.8$, $p < 0.001$.

from the study) of live patients with other types of hepatocellular carcinoma ($\chi^2 = 7.37$; $p < 0.01$).

None of the patients with fibrolamellar carcinoma or the three others with increased serum unsaturated vitamin B₁₂ binding capacity had a raised serum alpha-fetoprotein concentration. In contrast, 78 of 97 (81%) with normal serum unsaturated vitamin B₁₂ binding capacity had a raised serum alpha-fetoprotein concentration.

TABLE I—Clinicopathological details of 10 patients with hepatocellular carcinoma associated with increased unsaturated vitamin B₁₂ binding capacity

Patient	Age	Sex	UBBC (µg/l) (normal 0.7-1.6)	Vitamin B ₁₂ (ng/l) (normal 160-750 ng/l)	Specimen	Histology	Cirrhosis	Follow up (months)	Treatment
1	26	M	170.0		Needle	Fibrolamellar	No	Died (14)	Embolisation + adriamycin
2	20	M	39.5		Surgical	Fibrolamellar	No	Alive (15)	Embolisation + adriamycin
3	18	M	82.0		Surgical	Trabecular/acinar	No	Died (14)	Embolisation + adriamycin
4	20	F	379.0	995	Needle	Trabecular/acinar	No	Alive (22)	Adriamycin
5	16	F	183.0		Surgical	Fibrolamellar	No	Died (12)	Embolisation + adriamycin
6	28	F	29.6	1 345	Needle	Trabecular/acinar	No	Alive (4)	Adriamycin
7	16	M	144.0	3 500	Surgical	Fibrolamellar	No	Died (20)	Adriamycin
8	15	F	414.0	15 500	Needle	Fibrolamellar	No	Died (6)	Adriamycin
9	30	F	79.0	13 000	Resection	Fibrolamellar	No	Alive (50)	Resection + adriamycin
10	21	F	39.7	> 900	Resection	Fibrolamellar	No	Alive (10)	Resection + adriamycin

UBBC = Unsaturated vitamin B₁₂ binding capacity.

Intracellular globular inclusions were seen in seven of the eight fibrolamellar carcinomas. They were periodic acid Schiff-positive and diastase-resistant, although they stained less strongly than comparable inclusions known to consist of alpha-fetoprotein or alpha 1 anti-trypsin. On electronmicroscopy they appeared to correspond to electron-dense membrane-bound inclusions. Pale inclusions and similar material in cells and pseudoacini (probably the "pale bodies" of Craig *et al*³) stained more consistently with alcian blue and orcein methods, indicative of strongly sulphated acid glycoprotein content. They corresponded electron microscopically to granular and basement membrane-like material both free and within dilated endoplasmic reticulum lakes. In the fibrotic lamellar areas the main stromal cell was the fibroblast, although some macrophages were also seen. In the non-fibrotic areas the main stromal cell was endothelial. No lipocytes were seen.

Discussion

Our data show a hitherto unreported association between increased serum unsaturated vitamin B₁₂ binding capacity and the fibrolamellar histological pattern of hepatocellular carcinoma. Hepatocellular carcinoma was present in seven of the 10 patients with increased unsaturated vitamin B₁₂ binding capacity compared with only one of the other 97 patients in whom unsaturated vitamin B₁₂ binding capacity was not increased ($p < 0.001$). The three patients (cases 3, 4, and 6) with increased unsaturated vitamin B₁₂ binding capacity in whom no fibrosis was seen could very possibly also have had fibrolamellar carcinoma, since fibrosis in this type of tumour is not always present throughout the tumour, which may be trabecular or acinar in places.³ The association is, however, not complete, as shown by the one patient with fibrolamellar hepatocellular carcinoma and normal serum unsaturated vitamin B₁₂ binding capacity.

The increased serum unsaturated vitamin B₁₂ binding capacity in some previously reported cases of hepatocellular carcinoma was due to an increase in a vitamin B₁₂ binding protein which differs from normal transcobalamin I only in that it contains more sialic acid residues.^{7, 8} Whether it is produced by the tumour or stored and modified within it by addition of sialic acid has not been established. Transcobalamin I was not measured in this series, but it is of interest that acid glycoproteins were detected histochemically and basement membrane-like material electron microscopically. Whether these features are morphological manifestations of the presence of transcobalamin I must await the development of specific antibodies. It is not known if the presence of transcobalamin I could stimulate fibrogenesis, which is otherwise uncommon in hepatocellular carcinoma. In six patients with hepatocellular carcinoma associated with unsaturated vitamin B₁₂ binding capacity in whom vitamin B₁₂ was measured in the same pretreatment sera as unsaturated vitamin B₁₂ binding capacity, the concentration of vitamin B₁₂ was found to be raised (table I). A combination of serum unsaturated vitamin B₁₂ binding capacity and vitamin B₁₂ measurements may be more informative than estimations of unsaturated vitamin B₁₂ binding capacity alone, since marginal rises of transcobalamin can be masked by a high concentration of serum vitamin B₁₂.⁶

The description of a characteristic histological picture in addition to the previously reported clinical features makes tumours associated with unsaturated vitamin B₁₂ binding capacity a distinct subgroup of hepatocellular carcinoma. Determination of unsaturated vitamin B₁₂ binding capacity does not, however, replace histological diagnosis, since increased binding capacity in serum has been described in patients with disseminated neoplasms from other primary sites, particularly when hepatic metastases are present¹⁰; in these patients serum unsaturated vitamin B₁₂ binding capacity is seldom as high as in hepatocellular carcinoma associated with increased serum unsaturated vitamin B₁₂ binding capacity and patients have been older and in the terminal stages of their disease.

Our observations confirm earlier findings⁶ that changes in

serum unsaturated vitamin B₁₂ binding capacity, even in the absence of vitamin B₁₂ and transcobalamin I determinations, reflect disease progression. Serum unsaturated vitamin B₁₂ binding capacity thus seems to be a useful serum marker in this group, particularly since the main serum marker of hepatocellular carcinoma (namely alpha-fetoprotein) is consistently absent. Whereas serum alpha-fetoprotein behaves as if it reflects tumour cell mass, rising exponentially with time in the absence of effective treatment, unsaturated vitamin B₁₂ binding capacity changes much less appreciably. Serum alpha-fetoprotein concentrations may increase more than 10-fold between presentation, diagnosis, and death, whereas unsaturated vitamin B₁₂ binding capacity increased by a maximum of 75% in this series. It seems unlikely therefore that the actual increase in unsaturated vitamin B₁₂ binding capacity bears any direct relation to tumour size.

References

- 1 Edmondson HA. In: *Tumours of the liver and intrahepatic bile ducts*. 1st ed. Washington DC: Armed Forces Institute of Pathology, 1958:90-104.
- 2 Peters RL. Pathology of hepatocellular carcinoma. In: Okuda K, Peters RL, eds. *Hepatocellular carcinoma*. New York: John Wiley and Sons, 1976: 152-4.
- 3 Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. *Cancer* 1980;45:372-9.
- 4 Waxman S, Gilbert HS. A tumor-related vitamin B₁₂ binding protein in adolescent hepatoma. *N Engl J Med* 1973;289:1053-6.
- 5 Nexø E, Olesen H, Nørredam K, Schwartz M. A rare case of megaloblastic anaemia caused by disturbances in the plasma cobalamin binding proteins in a patient with hepatocellular carcinoma. *Scand J Haematol* 1975;14:320-7.
- 6 Kane SP, Murray-Lyon IM, Paradinas FJ, *et al*. Vitamin B₁₂ binding as a tumour marker for hepatocellular carcinoma. *Gut* 1978;19:1105-9.
- 7 Burger LR, Waxman S, Gilbert HS, Mehlman CS, Allen RH. Isolation and characterisation of a novel vitamin B₁₂-binding protein associated with hepatocellular carcinoma. *J Clin Invest* 1975;56:1262-70.
- 8 Nexø E, Olesen H, Christensen JM, Thomsen J, Kristiansen K. Characterisation of a cobalamin-binding plasma protein from a patient with hepatoma. *Scand J Clin Lab Invest* 1975;35:683-90.
- 9 Gottlieb C, Lau KS, Wasserman LR, Herbert V. Rapid charcoal assay for intrinsic factor (IF), gastric juice unsaturated B₁₂ binding capacity, antibody to IF and serum unsaturated B₁₂ binding capacity. *Blood* 1965;35:875-84.
- 10 Carmel R, Eisenberg L. Serum vitamin B₁₂ and transcobalamin abnormalities in patients with cancer. *Cancer* 1977;40:1348-53.

(Accepted 23 June 1982)

ONE HUNDRED YEARS AGO Mr Anthony Trollope's illness, which terminated fatally on Wednesday night, presents many points of medical interest. In January last he consulted Dr Murrell for shortness of breath on exertion, and other symptoms which had been attributed to angina pectoris. On inquiry, it was found that there had been no true anginal attack, but an examination disclosed the existence of an aortic diastolic murmur. It was decided that Mr Trollope should take a rest, and he accordingly went to Ireland for a holiday. In October he returned to town, and resumed his literary labours. On November 3rd he was suddenly seized with aphasia and paralysis of the right arm and leg, evidently due to embolism. At first there was great mental excitement, which was with difficulty subdued by the free administration of bromide of sodium. For some days he was able to utter only a few simple words, which served to express his wants, but, little by little, the power of language returned and the paralysed limbs regained power. Last week he had so far recovered as to take outdoor exercise, and there was every prospect of a speedy restoration to health. On Saturday last there was some return of the mental irritability, and it was apparent that further changes were taking place in the brain-substance. He gradually became comatose, and for the last three days of his life took nothing by mouth, with the exception of a little iced water. Predigested foods were used in the form of enemata, and suppositories of peptones were found useful. The immediate cause of death was congestion of the lungs. (*British Medical Journal*, 1882.)